Literature DB >> 7684218

Coronary artery bypass grafting in patients with chronic lymphocytic leukemia.

S J Finck1, K J Cockerill, J E Jeter, T A Orszulak.   

Abstract

Chronic lymphocytic leukemia is a disease of the elderly. It tends to have a variable clinical course. Because of the patients' immunologically dysfunctional state, there has been reluctance to perform open cardiac procedures because of concern about early postoperative sepsis leading to death. To assess the risk of coronary artery bypass grafting in elderly patients, the records of 26 patients (mean age, 69.6 +/- 4.9 years) with chronic lymphocytic leukemia who underwent coronary artery bypass grafting between January 1975 and July 1990 were retrospectively reviewed. Nineteen underwent isolated coronary artery bypass grafting, and 7 had combined procedures. The operative mortality rate was 7.7%. Postoperative infections developed in 6 patients (23.1%): pneumonia in 3 and sternal osteomyelitis, acute parotiditis, and bacteremia in 1 each. One of these 6 patients died of acute Serratia pneumonitis. Twenty-four patients (92.3%) were discharged from the hospital an average of 10.6 +/- 7.7 days postoperatively. Patients with chronic lymphocytic leukemia can undergo coronary artery bypass grafting with acceptable mortality but with increased risk of postoperative infection.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7684218     DOI: 10.1016/0003-4975(93)90032-d

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  2 in total

1.  Management and postoperative outcome in primary lung cancer and heart disease co-morbidity: a systematic review and meta-analysis.

Authors:  George D Bablekos; Antonis Analitis; Stylianos A Michaelides; Konstantinos A Charalabopoulos; Anastasia Tzonou
Journal:  Ann Transl Med       Date:  2016-06

2.  Can cardiac surgery be performed safely on patients with haematological malignancies.

Authors:  A Guler; M A Sahin; F Cingoz; E Ozal; U Demirkilic; M Arslan
Journal:  Cardiovasc J Afr       Date:  2012-05       Impact factor: 1.167

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.